Journal article

Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)

Grace Kong, Simona Grozinsky-Glasberg, Michael S Hofman, Tim Akhurst, Amichay Meirovitz, Ofra Maimon, Yodphat Krausz, Jeremy Godefroy, Michael Michael, David J Gross, Rodney J Hicks

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | SPRINGER | Published : 2019

Abstract

PURPOSE: Rectal neuroendocrine neoplasia (NEN) is more common than other NEN origins, but is less commonly metastatic. However, when present, distant disease carries a particularly poor prognosis. Evidence guiding optimal treatment of such patients is lacking. We assessed PRRT outcomes in patients with somatostatin receptor (SSTR) positive metastatic rectal NEN from two referral centres. METHODS: Patients treated with PRRT were retrospectively reviewed. Morphologic (RECIST 1.1), SSTR imaging responses and toxicity were assessed 3 months post-PRRT. Kaplan-Meier estimate was used to determine progression-free survival (PFS) and overall survival (OS) from start of PRRT. RESULTS: Twenty-seven co..

View full abstract